Scholarlink

Background <p>Pneumonia is a common and severe complication following spontaneous intracerebral hemorrhage (SICH) and is associated with significantly worse clinical outcomes. However, there remains insufficient evidence supporting empirical antibiotic regimens for SICH-associated pneumonia (SICHAP).</p> Objective <p>To evaluate the clinical efficacy of different empirical antibiotic regimens in patients with SICHAP and to provide evidence for optimizing initial antimicrobial strategies.</p> Methods <p>This single-center retrospective cohort study enrolled adult patients with SICH who developed pneumonia within 7 days of onset between July and December 2024. Patients were stratified according to their initial empirical antibiotic regimen: cefazolin (CFZ), ceftriaxone (CRO), cefoperazone-sulbactam (CFP-SUL), or piperacillin-tazobactam (PIP-TAZ). The primary outcome was the clinical efficacy rate at 72&#xa0;h. The secondary outcomes included the SICHAP treatment failure rate, in-hospital mortality, length of stay, duration of mechanical ventilation, and duration of antibiotic therapy. Treatment appropriateness was assessed on the basis of sputum culture and antimicrobial susceptibility testing.</p> Results <p>A total of 85 patients (mean age 54.2 ± 13.5 years, 63.5% male) were enrolled, with 90.6% presenting with early SICHAP. The 72-hour efficacy rate in the CFP-SUL group (73.3%) was significantly greater than that in the CFZ group (25.0%), CRO group (54.5%), and PIP-TAZ group (58.8%) (<i>p</i> = 0.022). The overall SICHAP treatment failure rate was 55.3%, with no significant intergroup differences (<i>p</i> = 0.137). In the sputum culture-positive subgroup (<i>n</i> = 49), appropriate empirical antibiotic therapy (AEAT) significantly reduced treatment failure (58.1% vs. 94.4%, <i>p</i> = 0.008). Pathogens were predominantly Gram-negative (75.3%), with the most common isolates being <i>Klebsiella pneumoniae</i> (42.9%), <i>Pseudomonas aeruginosa</i> (40.8%), and <i>Acinetobacter baumannii</i> (22.4%). High rates of ESBL production and carbapenemase detection were observed.</p> Conclusion <p>Among SICHAP patients, empirical CFP-SUL therapy demonstrated greater 72-hour clinical efficacy, and AEATs significantly reduced the risk of treatment failure. These findings suggest that CFP-SUL may be favored for early empirical antimicrobial therapy in this population, although prospective randomized controlled trials are needed to confirm these results.</p> Clinical trial <p>Clinical trial number: not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Empirical antibiotic therapy for spontaneous intracerebral hemorrhage-associated pneumonia: an ICU-based single-centered retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月16日

查看全文
  • Xuemei Tao,
  • Junwei Wang,
  • Jing Rao,
  • Junjie Zhong,
  • Zhou Shu,
  • Peishan Cai,
  • Qi Li,
  • Fang Zeng,
  • Jie Li

摘要

Background

Pneumonia is a common and severe complication following spontaneous intracerebral hemorrhage (SICH) and is associated with significantly worse clinical outcomes. However, there remains insufficient evidence supporting empirical antibiotic regimens for SICH-associated pneumonia (SICHAP).

Objective

To evaluate the clinical efficacy of different empirical antibiotic regimens in patients with SICHAP and to provide evidence for optimizing initial antimicrobial strategies.

Methods

This single-center retrospective cohort study enrolled adult patients with SICH who developed pneumonia within 7 days of onset between July and December 2024. Patients were stratified according to their initial empirical antibiotic regimen: cefazolin (CFZ), ceftriaxone (CRO), cefoperazone-sulbactam (CFP-SUL), or piperacillin-tazobactam (PIP-TAZ). The primary outcome was the clinical efficacy rate at 72 h. The secondary outcomes included the SICHAP treatment failure rate, in-hospital mortality, length of stay, duration of mechanical ventilation, and duration of antibiotic therapy. Treatment appropriateness was assessed on the basis of sputum culture and antimicrobial susceptibility testing.

Results

A total of 85 patients (mean age 54.2 ± 13.5 years, 63.5% male) were enrolled, with 90.6% presenting with early SICHAP. The 72-hour efficacy rate in the CFP-SUL group (73.3%) was significantly greater than that in the CFZ group (25.0%), CRO group (54.5%), and PIP-TAZ group (58.8%) (p = 0.022). The overall SICHAP treatment failure rate was 55.3%, with no significant intergroup differences (p = 0.137). In the sputum culture-positive subgroup (n = 49), appropriate empirical antibiotic therapy (AEAT) significantly reduced treatment failure (58.1% vs. 94.4%, p = 0.008). Pathogens were predominantly Gram-negative (75.3%), with the most common isolates being Klebsiella pneumoniae (42.9%), Pseudomonas aeruginosa (40.8%), and Acinetobacter baumannii (22.4%). High rates of ESBL production and carbapenemase detection were observed.

Conclusion

Among SICHAP patients, empirical CFP-SUL therapy demonstrated greater 72-hour clinical efficacy, and AEATs significantly reduced the risk of treatment failure. These findings suggest that CFP-SUL may be favored for early empirical antimicrobial therapy in this population, although prospective randomized controlled trials are needed to confirm these results.

Clinical trial

Clinical trial number: not applicable.